查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2106668

心臟節律器：市場洞察、競爭格局和市場預測 - 2034年

Pacemakers - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 據估計，2025年心臟心律調節器市值為64.9億美元，預計到2034年將達到105.1億美元。該成長是由全球心血管疾病和心搏過緩負擔加重、老年人口不斷成長以及無導線和MRI兼容型心律調節器平台的加速普及所推動的。
  • 全球心臟節律器市場預計在2026年至2034年的預測期內將以 5.5%的CAGR成長。
  • 就植入性而言，到2025年，雙腔心律調節器細分市場佔整個植入式心律調節器類別的52%，推動心律調節器市場的發展。
  • 依設備類型分類，到2025年，MRI 相容型心律調節器以 84%的市場佔有率引領心律調節器市場，其中無導線 MRI 相容型心律調節器的成長速度最快。
  • 就終端用戶而言，到2025年，醫院領域引領心臟心律調節器市場，佔 64%的市場佔有率。
  • 到2025年，北美佔全球心臟心律調節器市場銷售額的44%，在全球區域市場佔有率中佔據最高佔有率。

心臟節律器是一種小型、電池供電的醫療設備，通常皮下植入鎖骨附近，透過向心臟輸送電脈衝來調節心搏過緩、心臟傳導阻滯或相關傳導障礙患者的異常心率。現代心臟節律系統種類繁多，從傳統的單心室和雙心室經靜脈植入式心律調節器，到雙心室/心臟再同步治療（CRT）心律調節器，再到近年來透過導管直接植入心腔的無導線心律調節器。根據植入式心律調節器的植入方式，市場可進一步細分為單心室心律調節器、雙心室心律調節器、雙心室/CRT心律調節器以及用於急性或短暫性適應症的體外（暫時性）心律調節器。此外，根據心律調節器類型，市場還可細分為MRI相容型心律調節器和無導線MRI相容型心律調節器；並根據最終用戶，市場可細分為醫院、門診手術中心和其他醫療機構。受人口老化、心律不整和心臟衰竭盛行率上升、電池壽命延長、小型化、MRI相容性、傳導起搏技術的不斷創新以及遠端監測能力增強等因素的推動，心臟節律器已成為全球心臟節律管理設備行業的基礎性且穩步成長的類別。

心臟心律調節器市場的主要市場促進因素

  • 全球心血管疾病和心搏過緩負擔日益加重，推動了人工心臟植入率的上升。據估計，全球約有5.5億人患有心臟和循環系統疾病，光是冠狀動脈疾病就影響超過2.44億人。
  • 老年人口的成長是結構性利多因素，世界衛生組織預測，到2050年，60 歲及以上人口將幾乎加倍，達到 21億，而 80 歲及以上人口在同一時期將幾乎翻兩番。
  • 無導線心律調節器在臨床環境中的迅速普及，包括Medtronic的「Micra AV2/VR2」系統和Abbott公司的「Aveir VR/DR」系統，消除了經靜脈導線的必要性，降低了感染疾病和導線故障的風險，並擴大了可治療的患者範圍。
  • 持續的技術創新，包括 MRI 相容平台、傳導系統和左束支起搏（LBBAP）、自動遠端監測和延長電池壽命，日益擴大臨床適應症和更換週期。
  • 由於監管部門的批准和適應症的擴大，生理起搏的機會日益增加，例如Boston Scientific將其「INGEVITY+」起搏導線的FDA和CE認證範圍從2024年擴大到2025年，用於傳導系統起搏；以及Biotronik將其「Solia CSP S」導線的FDA批准於2026年生效。
  • 亞太地區競爭對手擴大生產和銷售基地，例如MicroPort Scientific計畫於2025年在中國市場推出 TEN 心律調節器系列產品，這推動高成長新興市場的產品可及性和可負擔性得到改善。
  • 結合已開發市場和新興市場償付制度的改進以及人們對心血管疾病認知的提高，預計到2034年，該市場將保持穩定的中等個位數成長。

推動心臟心律調節器市場成長的因素

市場促進因素

心血管疾病和心搏過緩的盛行率增加

心臟節律器市場最大的促進因素是全球心血管疾病、心律不整和傳導障礙負擔的日益惡化。據估計，2020年全球約有2.44億人患有冠狀動脈疾病，心臟和循環系統疾病影響全球整體約5.5億人，其中包括約2.9億女性和2.6億男性。隨著老齡化成長，心房顫動、病竇症候群和高度房室傳導阻滯的盛行率不斷上升，需要永久性心臟節律器輔助治療心搏過緩的患者群體也持續擴大。心臟節律器植入術是一種基於既定指南的治療方法，並且擁有可靠的長期治療效果資料，因此，疾病發病率的上升將直接且可預見地導致手術數量的增加，這將支撐市場成長直至2034年。

老年人口的成長

全球人口的快速老化是心臟節律器需求結構性成長的有利因素。這是因為心搏過緩和傳導障礙在老年族群中特別常見。根據世界衛生組織（WHO）估計，2020年全球60歲以上人口約10億，預計2050年將幾乎加倍，達到約21億。同時，預計同期80歲及以上人口將成長近三倍，達到約4.26億。隨著北美、歐洲以及亞太地區人口結構的變化，符合首次植入和設備更換條件的患者群體也將相應擴大，維持對傳統和無導線心律調節器的長期需求。

市場限制因素

儘管基本需求強勁，但心律調節器市場仍面臨諸多限制因素。先進心律調節器系統（尤其是無導線和核磁共振相容平台）的高昂初始成本，在價格敏感型市場和新興市場構成了購買障礙，限制了醫保償付的覆蓋範圍。因電池性能、導線絕緣故障或軟體缺陷引發的設備召回和安全相關現場行動，會削弱醫生和患者的信心，並導致代價高昂的補救措施。各地區漫長且不均衡的法規核准流程延長了產品上市時間，並推高了研發成本，尤其是對於新型無導線和傳導式起搏平台而言。在一些新興市場，訓練有素的電生理學家和心臟植入專家的短缺限制了手術數量，即使設備已經上市。與傳統經靜脈系統相關的植入後併發症，例如感染、導線脫落和囊袋侵蝕，仍然影響部分患者和醫療服務提供者的選擇。除了地區間償付方案和自付費用不同之外，亞太地區低成本本地製造商的價格壓力也導致整體市場價值成長進一步放緩，儘管預計在整個預測期內銷售量將繼續成長。

目錄

第1章 心臟節律器市場報告簡介

  • 調查範圍
  • 市場區隔
  • 市場先決條件

第2章 心臟節律器市場執行摘要

  • 市場概覽

第3章 心臟節律器市場關鍵因素分析

  • 心臟心律調節器市場：市場促進因素
    • 心血管疾病和心搏過緩的盛行率增加
    • 老年人口增加
    • 無導線心律調節器技術的迅速普及
    • 心臟節律器治療領域的持續技術創新
  • 心臟心律調節器市場的市場限制與挑戰
    • 高成本且保險賠償金額波動較大。
    • 醫療設備回想和移植後併發症
    • 法規複雜，專業人員短缺。
  • 心臟節律器市場：市場機會
    • 傳導系統和左束支區域的起搏擴張
    • 在新興市場和地區擴大製造地

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章 心臟節律器市場評估

  • 依植入性
    • 植入式心臟節律器
    • 體外心律調節器
  • 依設備類型
    • 核磁共振相容型心臟節律器
    • 無導線MRI相容型心臟節律器
  • 依最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 心臟節律器市場的競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章 心臟節律器市場的新創企業資金籌措和投資趨勢

第10章 心臟節律器市場：公司概況與產品概況

  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • LivaNova PLC
  • Shree Pacetronix Ltd.
  • OSCOR Inc.
  • MEDICO SpA
  • Lepu Medical Technology Co. Ltd.
  • MicroPort Scientific Corporation

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0021

Pacemakers Market Summary

Overview:

  • The Pacemakers market is estimated at USD 6.49 billion in 2025 and is projected to reach USD 10.51 billion by 2034. Growth is anchored in the rising global burden of cardiovascular disease and bradyarrhythmia, an expanding geriatric population, and accelerating adoption of leadless and MRI-conditional pacing platforms.
  • The global Pacemakers market is growing at a CAGR of 5.5% during the forecast period from 2026 to 2034.
  • By implantability, the dual-chamber pacemaker segment dominated the Pacemakers market with a 52% share in 2025, within the broader implantable pacemaker category.
  • By device type, the MRI-compatible pacemaker segment dominated the Pacemakers market with an 84% share in 2025, while leadless MRI-compatible pacemakers posted the fastest growth.
  • By end-user, the hospitals segment dominated the Pacemakers market with a 64% share in 2025.
  • North America dominated the global Pacemakers market revenue with a 44% share in 2025, representing the highest regional market share globally.

A pacemaker is a small, battery-powered medical device implanted under the skin, typically near the collarbone, that delivers electrical impulses to regulate an abnormal heart rhythm in patients with bradycardia, heart block, or related conduction disorders. Modern systems range from conventional single- and dual-chamber transvenous devices to biventricular/cardiac resynchronization therapy pacemakers and, most recently, catheter-delivered leadless devices implanted directly within a heart chamber. The market is organized by implantability across implantable pacemakers, further split into single-chamber, dual-chamber, and biventricular/CRT pacemakers, and external (temporary) pacemakers used for acute or transient indications; by device type across MRI-compatible and leadless MRI-compatible pacemakers; and by end-user across hospitals, ambulatory surgical centres, and other care settings. Driven by an aging population, rising prevalence of arrhythmias and heart failure, continuous innovation in battery longevity, miniaturization, MRI conditionality, and conduction system pacing, and expanding remote-monitoring connectivity, pacemakers remain a foundational and steadily growing category within the global cardiac rhythm management device industry.

Pacemakers Market Key Growth Drivers

  • The rising global burden of cardiovascular disease and bradyarrhythmia is expanding implant volumes, with heart and circulatory disease affecting an estimated 550 million people worldwide and coronary heart disease alone affecting over 244 million people.
  • The growing geriatric population is a structural tailwind, with the WHO projecting the number of people aged 60 and above to roughly double to 2.1 billion by 2050 and those aged 80 and above to nearly triple over the same period.
  • Rapid clinical adoption of leadless pacemakers, including Medtronic's Micra AV2/VR2 and Abbott's Aveir VR/DR systems, is expanding the addressable patient pool by eliminating transvenous leads and reducing infection and lead-failure risk.
  • Continuous technological innovation, including MRI-conditional platforms, conduction system and left bundle branch area pacing (LBBAP), automated remote monitoring, and longer battery life, is broadening clinical indications and replacement cycles.
  • Regulatory approvals and label expansions, such as Boston Scientific's 2024-2025 FDA and CE Mark expansions of INGEVITY+ pacing leads for conduction system pacing and Biotronik's 2026 FDA approval of the Solia CSP S lead, are widening the physiological pacing opportunity.
  • Expanding manufacturing and commercial footprints among Asia-Pacific-based competitors, including MicroPort Scientific's 2025 localized TEN pacemaker family launch in China, are improving access and affordability in high-growth emerging markets.
  • Improving reimbursement frameworks and rising cardiovascular-disease awareness across developed and emerging markets are together expected to sustain steady, mid-single-digit growth in the market through 2034.

Key Companies in Pacemakers Market

The competitive landscape is led by the following active device manufacturers:

  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • LivaNova PLC
  • Shree Pacetronix Ltd.
  • OSCOR Inc.
  • MEDICO S.p.A.
  • Lepu Medical Technology Co. Ltd.
  • MicroPort Scientific Corporation

Factors Contributing to the Growth of the Pacemakers Market

Market Drivers

Rising Prevalence of Cardiovascular Diseases and Bradyarrhythmia

The single most powerful driver of the Pacemakers market is the growing global burden of cardiovascular disease, arrhythmias, and conduction disorders. Coronary heart disease affected an estimated 244 million people worldwide in 2020, and heart and circulatory diseases collectively affect approximately 550 million people globally, including roughly 290 million women and 260 million men. As atrial fibrillation, sick sinus syndrome, and high-grade atrioventricular block become more prevalent with age, the pool of patients requiring bradycardia support through permanent pacing continues to expand. Because pacemaker implantation is a well-established, guideline-directed therapy with strong long-term outcomes data, rising disease incidence translates directly and predictably into growing procedure volumes, anchoring market growth through 2034.

Expanding Geriatric Population

The rapidly aging global population is a structural tailwind for pacemaker demand, since bradyarrhythmia and conduction system disease disproportionately affect older adults. The World Health Organization estimated that around one billion people were aged 60 or older in 2020, a figure projected to roughly double to approximately 2.1 billion by 2050, while the population aged 80 and above is expected to nearly triple over the same period to about 426 million. As this demographic shift unfolds across North America, Europe, and increasingly Asia-Pacific, the underlying patient base eligible for first-time implantation and device replacement expands correspondingly, sustaining long-run demand for both conventional and leadless pacing systems.

Market Restraints

Despite steady underlying demand, the Pacemakers market faces material constraints. The high upfront cost of advanced pacemaker systems, particularly leadless and MRI-conditional platforms, limits affordability and reimbursement-driven adoption in price-sensitive and emerging markets. Device recalls and safety-related field actions tied to battery performance, lead insulation failure, or software malfunction can erode physician and patient confidence and trigger costly corrective actions. Lengthy and heterogeneous regulatory pathways across geographies, particularly for novel leadless and conduction-system-pacing platforms, extend time to market and raise development costs. A shortage of trained electrophysiologists and cardiac implant specialists in several emerging markets constrains procedure volumes even where device access exists. Post-implantation complications, including infection, lead dislodgement, and pocket erosion associated with conventional transvenous systems, continue to weigh on some patient and provider preferences. Uneven reimbursement and out-of-pocket cost burden across geographies, together with pricing pressure from local low-cost manufacturers in Asia-Pacific, further tempers overall market value growth, even as unit volumes continue to expand across the forecast period.

Pacemakers Market Segment Analysis

The pacemakers market by implantability (implantable pacemaker [single-chamber pacemaker, dual-chamber pacemaker, and biventricular/CRT pacemaker], and external pacemaker), device type (MRI-compatible pacemaker and leadless MRI-compatible pacemaker), end-user (hospitals, ambulatory surgical centres, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Implantability

Dominant Subsegment: Dual-Chamber Pacemaker.

Dominant: Dual-Chamber Pacemaker ~ 52%

The dual-chamber pacemaker segment accounted for approximately 52% of the Pacemakers market in 2025, within the broader implantable pacemaker category, which itself represents roughly 86% of total market value. Dual-chamber (DDD) systems use separate leads in the right atrium and right ventricle, sensing intrinsic electrical activity in each chamber and preserving atrioventricular synchrony, which more closely mimics natural cardiac physiology than single-chamber pacing. This synchrony reduces the risk of pacemaker syndrome and atrial fibrillation, improves symptoms of heart failure, and modestly improves quality of life relative to ventricular-only pacing, making dual-chamber devices the default choice across most sinus node dysfunction and AV block indications. Single-chamber pacemakers retain a meaningful share in patients with permanent atrial fibrillation or isolated ventricular pacing needs, while biventricular/CRT pacemakers, though a smaller share, are growing steadily on the back of expanding heart-failure indications. External (temporary) pacemakers serve acute, transient bradycardia needs in critical-care and peri-procedural settings and represent the remainder of the implantability segment. While leadless and CRT platforms are growing fastest, the clinical breadth and procedural familiarity of dual-chamber pacing secure its leadership across the forecast period.

By Device Type

Dominant Subsegment: MRI Compatible Pacemaker.

Dominant: MRI Compatible Pacemaker ~ 84%

The MRI compatible pacemaker segment accounted for approximately 84% of the Pacemakers market in 2025. Conventional transvenous MRI-conditional systems, such as Biotronik's Entovis and Amvia Edge families, Medtronic's Azure XT DR MRI SureScan platform, Boston Scientific's Accolade MRI, and Abbott's Assurity MRI, remain the default choice for most first-time implants because they are compatible with the widest range of pacing indications, offer the deepest base of long-term clinical evidence, and are broadly reimbursed across major markets. MRI conditionality itself has become a near-standard feature rather than a premium add-on, reflecting the clinical need for patients to safely access diagnostic MRI scans without pre- or post-scan reprogramming. Leadless MRI compatible pacemakers, led by Medtronic's Micra AV2/VR2 and Abbott's Aveir VR/DR platforms, represent the fastest-growing device type as physician experience broadens and dual-chamber leadless synchronization technology matures, but their share remains constrained by higher unit costs, narrower indication profiles, and the need for specialized catheter-based implantation skills. The combination of established clinical evidence, broad indication coverage, and near-universal reimbursement secures the leadership of MRI-compatible transvenous pacemakers through 2034.

Pacemakers Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Pacemakers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a well-established cardiac care infrastructure, a large and aging population with a high prevalence of cardiovascular disease, favorable and predictable reimbursement frameworks, and rapid adoption of premium technologies such as leadless and MRI-conditional pacemakers. The United States Centers for Disease Control and Prevention estimated that about 20.1 million American adults aged 20 and older had coronary artery disease in 2020, and that someone in the country experiences a heart attack roughly every 40 seconds. A dense concentration of leading manufacturers, including Medtronic, Boston Scientific, and Abbott, together with steady FDA approvals of next-generation leadless and conduction-system-pacing devices, reinforces the region's technology leadership and continued market share through the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Pacemakers market. The region's elevated CAGR is driven by rising cardiovascular disease incidence, expanding hospital-based cardiac care infrastructure, growing government healthcare investment, and the localization of manufacturing by both global and domestic players across China, Japan, India, South Korea, and Australia. MicroPort Scientific Corporation's March 2025 launch of its localized TEN pacemaker family in China illustrates the region's shift toward affordable, domestically manufactured devices tailored to local regulatory and clinical needs. China's expanding cardiac catheterization capacity, Japan's aging population and steady technology adoption, and India's growing private hospital network are collectively accelerating implant volumes. The combination of rising disease burden, improving reimbursement access, and local manufacturing scale-up positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Pacemakers market revenue in 2025. The United States dominates on the strength of its cardiac care infrastructure, high cardiovascular disease burden, favorable reimbursement, and the concentrated presence of leading global manufacturers, while steady regulatory approvals of leadless and conduction-system-pacing technologies reinforce the region's continued technology leadership.

Europe

Europe is a large and technologically advanced regional market, supported by established CE Mark regulatory pathways, strong national reimbursement systems, and a deep base of cardiac rhythm management expertise anchored by manufacturers such as Biotronik and, historically, LivaNova's cardiac rhythm management heritage before its 2018 divestment to MicroPort. Regulatory momentum, including Boston Scientific's 2025 CE Mark expansion for conduction system pacing indications, reinforces the region's role as an early-adoption market for physiological pacing technologies across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, expanding hospital infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. MicroPort Scientific's localized device launches in China, Lepu Medical's expanding domestic device portfolio, and Japan's steady adoption of advanced leadless technology are accelerating regional growth and narrowing the historical technology-access gap with North America and Europe.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac care infrastructure, rising diagnosis rates for arrhythmias and conduction disorders, and gradual improvement in reimbursement and insurance coverage are broadening access, while international partnerships and technology-transfer arrangements support the gradual build-out of regional implantation capacity.

Pacemakers Market Competitive Landscape

The Pacemakers market is classified as Moderately Consolidated. A group of large, diversified medical technology leaders, including Medtronic, Boston Scientific, and Biotronik, anchor the top tier through broad product portfolios, deep clinical evidence, and global commercial reach, while specialized and regional manufacturers such as Shree Pacetronix, OSCOR, MEDICO S.p.A., Lepu Medical Technology, and MicroPort Scientific compete through focused product lines, competitive pricing, and strong positions in domestic or niche markets, increasing competitive intensity in price-sensitive and fast-growing geographies.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with a small number of global leaders anchoring premium technology segments and a broader field of regional and specialized manufacturers competing on price and local access.
  • Leading players: Medtronic, Boston Scientific, and Biotronik anchor the top tier through leadless pacing, conduction-system-pacing, and MRI-conditional technology leadership.
  • Geographic reach: Leading players operate global commercial and manufacturing networks, while companies such as MicroPort Scientific and Lepu Medical concentrate strength in China and broader Asia-Pacific markets.
  • Product portfolio strength: Top players offer end-to-end pacing portfolios spanning single- and dual-chamber, biventricular/CRT, and leadless systems, complemented by dedicated conduction-system-pacing leads.
  • Technology access: Leadership in leadless pacing, MRI conditionality, and conduction system/LBBAP pacing, including proprietary technologies such as Medtronic's Micra platform and Biotronik's Solia CSP S lead, is a decisive competitive advantage.
  • Strategic partnerships: Regional joint ventures and licensing arrangements, such as the historical LivaNova-MicroPort cardiac rhythm management transaction and MicroPort's China-focused affiliate structure, extend market reach.
  • M&A and portfolio activity: Ongoing portfolio realignment, including MicroPort CardioFlow's 2025 merger with MicroPort CRM to build an integrated cardiac diagnosis and therapy platform, reflects active consolidation within the broader cardiac rhythm management space.
  • Manufacturing capabilities: Automated, high-precision manufacturing of miniaturized pulse generators and pacing leads, together with rigorous quality and reliability testing, forms a key competitive moat.
  • Innovation focus: Leadless and dual-chamber leadless pacing, conduction system pacing (LBBAP), extended battery longevity, MRI conditionality, and remote-monitoring connectivity define the current innovation frontier.

Pacemakers Market Recent Developmental Activities

In 2026, Biotronik SE & Co. KG received FDA approval for its Solia CSP S pacing lead, purpose-built for left bundle branch area pacing (LBBAP), combining a stylet-driven lead platform with a newly designed fixed helix. Strategic significance: Reinforces Biotronik's leadership in physiological, conduction-system pacing technology.

In December 2025, MicroPort Scientific Corporation announced that its subsidiary MicroPort CardioFlow's strategic merger with MicroPort Cardiac Rhythm Management, structured as a share-based transaction valued at approximately USD 680 million, was approved by shareholders. Strategic significance: Builds an integrated structural heart, rhythm management, and heart failure platform.

Pacemakers Market Segmentation

Pacemakers Market by Implantability

  • Implantable Pacemaker
  • Single-Chamber Pacemaker
  • Dual-Chamber Pacemaker
  • Biventricular/CRT Pacemaker
  • External Pacemaker

Pacemakers Market by Device Type

  • MRI Compatible Pacemaker
  • Leadless MRI Compatible Pacemaker

Pacemakers Market by End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Pacemakers Market by Geography

  • North America Pacemakers Market
  • United States Pacemakers Market Size in USD million (2023-2034)
  • Canada Pacemakers Market Size in USD million (2023-2034)
  • Mexico Pacemakers Market Size in USD million (2023-2034)
  • Europe Pacemakers Market
  • Germany Pacemakers Market Size in USD million (2023-2034)
  • United Kingdom Pacemakers Market Size in USD million (2023-2034)
  • France Pacemakers Market Size in USD million (2023-2034)
  • Italy Pacemakers Market Size in USD million (2023-2034)
  • Spain Pacemakers Market Size in USD million (2023-2034)
  • Rest of Europe Pacemakers Market Size in USD million (2023-2034)
  • Asia-Pacific Pacemakers Market
  • China Pacemakers Market Size in USD million (2023-2034)
  • Japan Pacemakers Market Size in USD million (2023-2034)
  • India Pacemakers Market Size in USD million (2023-2034)
  • Australia Pacemakers Market Size in USD million (2023-2034)
  • South Korea Pacemakers Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Pacemakers Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Pacemakers Market
  • Middle East Pacemakers Market Size in USD million (2023-2034)
  • Africa Pacemakers Market Size in USD million (2023-2034)
  • South America Pacemakers Market Size in USD million (2023-2034)

Key Takeaways from the Pacemakers Market Report Study

  • Market size analysis for the current pacemakers market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global pacemakers market.
  • Various opportunities available for competitors in the pacemakers market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current pacemakers market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for pacemakers market growth in the future?

Target audience who can benefit from this Pacemakers market report study

  • Pacemakers product providers
  • Research organizations and consulting companies
  • Pacemakers-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in pacemakers
  • Various end-users who want to know more about the pacemakers market and the latest technological developments in the pacemakers market.

Frequently Asked Questions:

Q1. What is the growth rate of the pacemakers market?

The Pacemakers market is projected to expand at a CAGR of 5.5% during the forecast period from 2026-2034.

Q2. What is the market size of the pacemakers market?

The Pacemakers market is estimated at USD 6.49 billion in 2025 and is projected to reach USD 10.51 billion by 2034.

Q3. Which region dominates the pacemakers market?

North America dominated the pacemakers market with a 44% share of global revenue in 2025, supported by a well-established cardiac care infrastructure, high cardiovascular disease prevalence, favorable reimbursement, and the concentrated presence of leading global manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Pacemakers market?

The principal drivers are the rising global prevalence of cardiovascular disease and bradyarrhythmia; the rapidly expanding geriatric population, with the WHO projecting the population aged 60 and above to roughly double to 2.1 billion by 2050; rapid adoption of leadless pacemaker technology; continuous innovation in conduction system and left bundle branch area pacing; and expanding remote-monitoring connectivity.

Q5. Who are the major players in the pacemakers market?

The major players include Medtronic, Inc., St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., and MicroPort Scientific Corporation, among other active providers profiled in the Competitive Landscape section. Medtronic, Boston Scientific, and Biotronik lead through leadless and conduction-system-pacing technology.

Table of Contents

1. Pacemakers Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Pacemakers Market Executive Summary

  • 2.1 Market at a Glance

3. Pacemakers Market Key Factors Analysis

  • 3.1 Pacemakers Market Drivers
    • 3.1.1 Rising Prevalence of Cardiovascular Diseases and Bradyarrhythmia
    • 3.1.2 Expanding Geriatric Population
    • 3.1.3 Rapid Adoption of Leadless Pacemaker Technology
    • 3.1.4 Continuous Technological Innovation in Pacing Therapy
  • 3.2 Pacemakers Market Restraints and Challenges
    • 3.2.1 High Device Cost and Reimbursement Variability
    • 3.2.2 Device Recalls and Post-Implantation Complications
    • 3.2.3 Regulatory Complexity and Specialist Workforce Constraints
  • 3.3 Pacemakers Market Opportunities
    • 3.3.1 Conduction System and Left Bundle Branch Area Pacing Expansion
    • 3.3.2 Emerging-Market and Regional Manufacturing Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Pacemakers Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Pacemakers Market Assessment

  • 7.1 By Implantability
    • 7.1.1 Implantable Pacemaker
      • 7.1.1.1 Single-Chamber Pacemaker
      • 7.1.1.2 Dual-Chamber Pacemaker
      • 7.1.1.3 Biventricular/CRT Pacemaker
    • 7.1.2 External Pacemaker
  • 7.2 By Device Type
    • 7.2.1 MRI Compatible Pacemaker
    • 7.2.2 Leadless MRI Compatible Pacemaker
  • 7.3 By End-User
    • 7.3.1 Hospitals
    • 7.3.2 Ambulatory Surgical Centres
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Pacemakers Market Size in USD million (2023-2034)
      • 7.4.1.2 Canada Pacemakers Market Size in USD million (2023-2034)
      • 7.4.1.3 Mexico Pacemakers Market Size in USD million (2023-2034)
    • 7.4.2 Europe
      • 7.4.2.1 Germany Pacemakers Market Size in USD million (2023-2034)
      • 7.4.2.2 United Kingdom Pacemakers Market Size in USD million (2023-2034)
      • 7.4.2.3 France Pacemakers Market Size in USD million (2023-2034)
      • 7.4.2.4 Italy Pacemakers Market Size in USD million (2023-2034)
      • 7.4.2.5 Spain Pacemakers Market Size in USD million (2023-2034)
      • 7.4.2.6 Rest of Europe Pacemakers Market Size in USD million (2023-2034)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Pacemakers Market Size in USD million (2023-2034)
      • 7.4.3.2 Japan Pacemakers Market Size in USD million (2023-2034)
      • 7.4.3.3 India Pacemakers Market Size in USD million (2023-2034)
      • 7.4.3.4 Australia Pacemakers Market Size in USD million (2023-2034)
      • 7.4.3.5 South Korea Pacemakers Market Size in USD million (2023-2034)
      • 7.4.3.6 Rest of Asia-Pacific Pacemakers Market Size in USD million (2023-2034)
    • 7.4.4 Rest of World
      • 7.4.4.1 Middle East Pacemakers Market Size in USD million (2023-2034)
      • 7.4.4.2 Africa Pacemakers Market Size in USD million (2023-2034)
      • 7.4.4.3 South America Pacemakers Market Size in USD million (2023-2034)

8. Pacemakers Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Pacemakers Market Startup Funding and Investment Trends

10. Pacemakers Market Company and Product Profiles

  • 10.1 Medtronic, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 St. Jude Medical, Inc.
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Boston Scientific Corporation
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Biotronik SE & Co. KG
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 LivaNova PLC
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Shree Pacetronix Ltd.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 OSCOR Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 MEDICO S.p.A.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Lepu Medical Technology Co. Ltd.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10. 10 MicroPort Scientific Corporation
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Pacemakers Market in Global (2023-2034)
  • Table 2: Pacemakers Market in Global by Implantability (2023-2034)
  • Table 3: Pacemakers Market in Global by Device Type (2023-2034)
  • Table 4: Pacemakers Market in Global by End-Users (2023-2034)
  • Table 5: Pacemakers Market in Global by Geography (2023-2034)
  • Table 6: Pacemakers Market in North America (2023-2034)
  • Table 7: Pacemakers Market in the United States (2023-2034)
  • Table 8: Pacemakers Market in Canada (2023-2034)
  • Table 9: Pacemakers Market in Mexico (2023-2034)
  • Table 10: Pacemakers Market in Europe (2023-2034)
  • Table 11: Pacemakers Market in Germany (2023-2034)
  • Table 12: Pacemakers Market in United Kingdom (2023-2034)
  • Table 13: Pacemakers Market in France (2023-2034)
  • Table 14: Pacemakers Market in Italy (2023-2034)
  • Table 15: Pacemakers Market in Spain (2023-2034)
  • Table 16: Pacemakers Market in the Rest of Europe (2023-2034)
  • Table 17: Pacemakers Market in Asia-Pacific (2023-2034)
  • Table 18: Pacemakers Market in China (2023-2034)
  • Table 19: Pacemakers Market in Japan (2023-2034)
  • Table 20: Pacemakers Market in India (2023-2034)
  • Table 21: Pacemakers Market in Australia (2023-2034)
  • Table 22: Pacemakers Market in South Korea (2023-2034)
  • Table 23: Pacemakers Market in Rest of Asia-Pacific (2023-2034)
  • Table 24: Pacemakers Market in the Rest of the World (2023-2034)
  • Table 25: Pacemakers Market in the Middle East (2023-2034)
  • Table 26: Pacemakers Market in Africa (2023-2034)
  • Table 27: Pacemakers Market in South America (2023-2034)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Pacemakers Market Drivers
  • Figure 2: Pacemakers Market Restraints
  • Figure 3: Pacemakers Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Pacemakers Market in Global (2023-2034)
  • Figure 9: Pacemakers Market in Global by Implantability (2023-2034)
  • Figure 10: Pacemakers Market in Global by Device Type (2023-2034)
  • Figure 11: Pacemakers Market in Global by End-Users (2023-2034)
  • Figure 12: Pacemakers Market in Global by Geography (2023-2034)
  • Figure 13: Pacemakers Market in North America (2023-2034)
  • Figure 14: Pacemakers Market in the United States (2023-2034)
  • Figure 15: Pacemakers Market in Canada (2023-2034)
  • Figure 16: Pacemakers Market in Mexico (2023-2034)
  • Figure 17: Pacemakers Market in Europe (2023-2034)
  • Figure 18: Pacemakers Market in Germany (2023-2034)
  • Figure 19: Pacemakers Market in United Kingdom (2023-2034)
  • Figure 20: Pacemakers Market in France (2023-2034)
  • Figure 21: Pacemakers Market in Italy (2023-2034)
  • Figure 22: Pacemakers Market in Spain (2023-2034)
  • Figure 23: Pacemakers Market in the Rest of Europe (2023-2034)
  • Figure 24: Pacemakers Market in Asia-Pacific (2023-2034)
  • Figure 25: Pacemakers Market in China (2023-2034)
  • Figure 26: Pacemakers Market in Japan (2023-2034)
  • Figure 27: Pacemakers Market in India (2023-2034)
  • Figure 28: Pacemakers Market in Australia (2023-2034)
  • Figure 29: Pacemakers Market in South Korea (2023-2034)
  • Figure 30: Pacemakers Market in Rest of Asia-Pacific (2023-2034)
  • Figure 31: Pacemakers Market in the Rest of the World (2023-2034)
  • Figure 32: Pacemakers Market in the Middle East (2023-2034)
  • Figure 33: Pacemakers Market in Africa (2023-2034)
  • Figure 34: Pacemakers Market in South America (2023-2034)
  • Figure 35: Competitive Landscape
  • Figure 36: Startup Funding and Investment Trends